TGN-1412 victims' lawyers hold talks with Parexel

19 March 2007

One year on from the disasterous trial of TGN-1412, which left volunteers fighting for their lives (Marketletter March 27, 2006), compensation of just L10,000 ($19,337) per person, from an insurance fund of L2.0 million, has been paid to those involved, according to a report on the BBC web site. The news has enlivened the Association of the British Pharmaceutical Industry's current debate on the need for the correct level of insurance provision for clinical trials (Marketletter March 13).

"Positive approach" from Parexel's insurers

Lawyers from London, UK-based law firm Leigh Day & Co, which represents four of those injured, met with Parexel, the USA-based clinical research company that conducted the study, on March 13 to begin interim talks to try and resolve the legal claims, without the need to begin court proceedings.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight